Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GNRHR | P30968 | 2/20 | 0.65 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | APLNR | P35414 | 5/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30773556 | 1.00 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1652722 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL22289009 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL5079698 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1371630 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL16815056 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL11678163 | 0.96 | PTGS1 (0.73) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29425250 | 0.96 | GNRHR (0.70) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL29459903 | 0.96 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29373920 | 0.96 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117462693-A | XTEN conjugate compositions and methods of making the same | 阿穆尼克斯运营公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230338575-A1 | COBALT-DOPED IRON OXIDE NANOPARTICLES AND METHODS FOR MAKING AND USING | OREGON STATE UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| CN-111971060-B | Bifunctional molecules that recruit antibodies and target tumor cells | 江南大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20230060997-A1 | RADIONUCLIDE-LHRH CONJUGATES FOR DIAGNOSIS OF REPRODUCTIVE CANCERS | Eastern Kentucky University | 2023-03-02 | — | — | US | disclosed |
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210290787-A1 | MACROCYCLE CONJUGATES | LUMIPHORE, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20050004000-A1 | Oral absorbed drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2005-01-06 | — | — | US | disclosed |
| EP-1383538-A2 | ORAL ABSORBED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. (IL) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002078597-A2 | ORAL ABSORBED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. WEIZMANN INSTITUTE OF SCIENCE (IL) | 2002-10-10 | — | — | WO | disclosed |
| US-4338305-A | LUTEINIZING HORMONE RELEASING HORMONE; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060997-A1 | RADIONUCLIDE-LHRH CONJUGATES FOR DIAGNOSIS OF REPRODUCTIVE CANCERS | LHCGR, GNRHR, FSHR | PTGS1 4748/4885GNRHR 2/4885ABCC2 4186/4885 |
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | ERBB3, ERBB2, PANK2 | PTGS1 1852/4885GNRHR 3907/4885ABCC2 359/4885 |
| US-20210290787-A1 | MACROCYCLE CONJUGATES | FOLH1, KLK3, CD47 | PTGS1 3282/4885GNRHR 85/4885ABCC2 2911/4885 |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | ERBB3, ERBB2, PANK2 | PTGS1 1852/4885GNRHR 3907/4885ABCC2 359/4885 |
| US-20230338575-A1 | COBALT-DOPED IRON OXIDE NANOPARTICLES AND METHODS FOR MAKING AND USING | FECH, CD63, ENO1 | PTGS1 635/4885GNRHR 356/4885ABCC2 3418/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | PTGS1 3385/4885GNRHR 937/4885ABCC2 1527/4885 |
| US-20050004000-A1 | Oral absorbed drugs | TPMT, CYP2C9, SLCO2B1 | PTGS1 1060/4885GNRHR 2250/4885ABCC2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.